Philippines: Sanofi Pasteur on Dengvaxia vaccine by George Buid
The Sanofi Pasteur held a press conference regarding the dengvaxia vaccine that they supplied to the Philippine government. It held controversy about how save the vaccine is if person is not yet infected with dengue. They presented new findings and analysis demonstrating the new profile of the vaccine. It was also stated by representatives that most are already infected with dengue that they didn't know it. Issue was also raised the cost of acquiring the vaccine that supplied dengue drive by the government which cost Php 3.5 Billion.
About dengue vaccine
The dengue vaccine does not contain viruses that can make people ill with dengue or severe dengue. Severe dengue infections are uncommon complications of dengue disease, occurring in an estimated 0.5% of cases manifesting symptoms of dengue annually.
Sanofi Pasteur’s dengue vaccine has been clearly proven to be safe and effective in the prevention of dengue in people 9 years of age and older living in endemic settings. Phase III clinical studies conducted in over 30,000 study participants from 10 countries in Latin America and Asia show a pooled efficacy of 65.6% against all four serotypes of dengue; 80% efficacy against hospitalizations due to dengue and 93% efficacy against severe disease in the study population 9 years of age and older over the 25 month follow up period of the study program.
The continuing long-term safety evaluation of the vaccine shows significantly fewer hospitalizations due to dengue in vaccinated vs. unvaccinated participants 9 years and older.
You must be logged in to use lightbox functionality